Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2026)

Vertex Pharmaceuticals' Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 15.86% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $2.9 billion (up 15.86% YoY), while the FY2025 annual figure was $2.9 billion, up 24.31% from the prior year.
• Long-Term Deferred Tax was $2.9 billion for Q1 2026 at Vertex Pharmaceuticals, up from $2.9 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $2.9 billion in Q1 2026 to a low of $945.5 million in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $2.0 billion across 5 years, with a median of $2.0 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax surged 48.71% in 2023, then rose 15.86% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.2 billion in 2022, then surged by 45.33% to $1.8 billion in 2023, then advanced by 28.64% to $2.3 billion in 2024, then advanced by 24.31% to $2.9 billion in 2025, then rose by 1.72% to $2.9 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $2.9 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.9 billion (Q3 2025), per Business Quant data.